Ernexa Therapeutics Inc.
ERNA
$1.15
-$0.05-4.17%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -29.82% | -3.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -20.31% | -8.39% | |||
| Operating Income | 20.31% | 8.39% | |||
| Income Before Tax | 60.65% | 61.73% | |||
| Income Tax Expenses | 100.00% | -62.50% | |||
| Earnings from Continuing Operations | 60.50% | 61.73% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 60.50% | 61.73% | |||
| EBIT | 20.31% | 8.39% | |||
| EBITDA | 20.45% | 8.41% | |||
| EPS Basic | 75.20% | 73.65% | |||
| Normalized Basic EPS | 60.50% | 73.71% | |||
| EPS Diluted | 75.20% | 73.65% | |||
| Normalized Diluted EPS | 60.50% | 73.71% | |||
| Average Basic Shares Outstanding | 58.83% | 45.58% | |||
| Average Diluted Shares Outstanding | 58.83% | 45.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||